Operating profit before deduction of amortization: Pharming Group (PHAR)
Pharming Group N.V. relies on transparent European governance and global distribution networks. Diversification through the treatment of orphan diseases balances research and development costs. This chart on GURU.Markets shows that EBITDA currently stands at 46.54, serving as a navigator for cash flow. Meanwhile, reliance on third-party CMO plants is mitigated by long-term contracts.
Pharming Group (PHAR) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio Pharming Group N.V.|PHAR - Long-Term Debt to Capital|Current Liabilities to Capital Pharming Group NV|PHAR - Company Debts|Debts to Book Capitalization Ratio Pharming Group|PHAR - Company Long-Term Debts|Company Short-Term Loans and Borrowings Pharming Group|Quick Ratio pharming.com
- earnings and multiples data:
PHAR - Company Net Income|Expected Net Income Pharming Group N.V.|PHAR - Price to Earnings Ratio|Projected Price to Earnings pharming.com|PHAR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pharming Group|PHAR - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Pharming Group|PHAR - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year pharming.com|PHAR - Net earnings per share growth this year|Expected earnings per share trend next year Pharming Group N.V.
Analysis of all company metrics:Pharming Corp, PHAR
Absolute operating profit measures the cash flow from core operations before depreciation and interest. This metric determines the business's actual ability to generate cash flows, excluding the impact of accounting policies. By analyzing absolute EBITDA trends, an investor assesses the resilience of profits to external shocks. For Pharming Group N.V. (PHAR), the stability of this line confirms market dominance in the orphan drug segment. The absence of competitors allows the company to maintain high margins and minimize revenue volatility.
Who Pharming Group N.V. competes with
Operating income before deduction of amortization argenx BVBA (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax S.A. (ABVX) - Operating profit before deduction of amortization|ADMA Biologics, Inc. (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Protagonist Therapeutics, Inc.|Operating profit before deduction of amortization IMVT|Operating profit EBITDA Kiniksa Corp|Profit before payment of interest, taxes and amortization Grifols, S.A. (GRFS)|adaptivebiotech.com - Operating profit before amortization|Operating profit EBITDA CLDX (Celldex Therapeutics, Inc.)|Aurinia Pharmaceuticals Inc (AUPH) - Profit before interest, taxes and amortization|BCRX - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization VERA|DNTH: Operating profit EBITDA|pharvaris.com - Income before deduction of interest, taxes and amortization|ABCL (AbCellera Biologics Inc.) - Operating profit EBITDA|Operating profit EBITDA Tourmaline Bio Inc|Profit before payment of interest, taxes and amortization Intrexon (PGEN)|NKTR (Nektar Corp) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Upstream Bio Inc UPB|ZBIO - Operating profit before deduction of amortization|Immunome - Operating profit EBITDA|Operating income before deduction of amortization Gossamer Bio Inc GOSS|KalVista Pharmaceuticals Inc (KALV) - Profit before payment of interest, taxes and amortization|Operating profit before amortization SEPN|PVLA (Pieris Pharmaceuticals) - Operating profit EBITDA|SVRA - Operating profit before depreciation charges|Operating profit before deduction of amortization RIGL (Rigel Pharmaceuticals, Inc.)|ANAB (AnaptysBio Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ATXS (Astria Pharma)|Operating profit before depreciation charges enGene Corp|RAPT - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization JBIO (Aerovate Therapeutics Inc)|Aclaris Therapeutics, Inc. (ACRS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Kyverna Therapeutics Inc. (KYTX)|Operating profit before deduction of amortization TLSA|Operating profit EBITDA Cabaletta Bio Inc|Profit before payment of interest, taxes and amortization Ventyx Biosciences (VTYX)|THTX: Profit before deduction of interest, taxes, depreciation and amortization|Avalo Therapeutics - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization ELDN|AGEN - Profit before payment of interest, taxes and amortization|CLYM (Climb Bio, Inc) - Operating profit before amortization|ZURA (Zura Bio) - Operating profit before deduction of amortization|ATYR - Operating income before deduction of amortization|Operating profit before deduction of amortization ADAG|Profit before payment of interest, taxes and amortization IMA|Operating profit before deduction of amortization STTK (Shattuck Labs, Inc.)|Operating income before deduction of amortization equilliumbio.com|Profit before payment of interest, taxes and amortization Connect Biopharma Holdings Limited CNTB|IMUX (Immunic Therapeutics) - Profit before deduction of interest, taxes, depreciation and amortization|Atara Biotherapeutics Inc - Operating profit EBITDA|Income before deduction of interest, taxes and amortization IFRX (InflaRx N.V.)|XFOR: Operating profit EBITDA|Adicet Bio, Inc. (ACET) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Celularity Inc|INMB: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Barinthus Biotherapeutics plc (BRNS)|KZR: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA SABS (SAB Biotherapeutics, Inc)|Income before deduction of interest, taxes and amortization AKTX|Enlivex Therapeutics, Ltd. - Operating profit EBITDA|QTTB - Operating profit EBITDA|GeoVax (GOVX) - Profit before payment of interest, taxes and amortization|Edesa Biotech Inc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization iBio Corp|Operating profit before deduction of amortization Carisma Tx (CARM)|Operating profit EBITDA XTLB|Operating profit EBITDA boltbio.com (BOLT)|HCW Biologics - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization APVO|AIM ImmunoTech Inc. - Operating profit EBITDA|Operating income before deduction of amortization Aditxt ADTX|GRI Bio, Inc. (GRI) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization xortx.com|Profit before payment of interest, taxes and amortization Vyome Holdings|Operating profit before deduction of amortization Revelation Biosciences Inc (REVB)|Operating profit before deduction of amortization INDP (Indaptus)|Operating profit EBITDA BiondVax Pharmaceuticals (SCNI)|Profit before payment of interest, taxes and amortization CalciMedica CALI|AFMD: Operating profit before amortization|Allakos Therapeutics - Operating profit EBITDA|Profit before interest, taxes and amortization HOOKIPA Pharma Inc.|igmbio.com (IGMS) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization ITOS (iTeos Pharma)|OCEA (Ocean Biomedical, Inc.) - Operating profit EBITDA|TCBP: Income before deduction of interest, taxes and amortization|Operating profit EBITDA THRD
